Citations

Showing 10 of 107851 citations.

Kinematics and Laxity of Ulnohumeral Joint Under Valgus-Varus Stress
Tanaka, Shinji , An, Kai‐Nan , Morrey, B.F.

Mayo Clinic

Journal of Musculoskeletal Research | June 19, 2003 | Volume: 02 | Issue: 01 | Pages: 45-54

10.1142/s021895779800007x Get It

Three-dimensional kinematics of the ulnohumeral joint under simulated active elbow joint flexion-extension was obtained by using an electromagnetic tacking device. The joint motion was analyzed based on Eulerian angle description. In order to minimize the effect of "downstream cross-talk" on calculation of the three Eulerian angles, an optimal axis to best represent flexion-extension of the elbow joint was established. This axis, on average, is close to the line joining the centers of the capitellum and the trochlear groove. Furthermore, joint laxity under valgus-varus stress was also examined. With the weight of the forearm as the stress, maximums of 7.6° valgus-varus laxity and 5.3° axial rotation laxity were observed within a range of elbow flexion. The results of this study provide useful baseline information on joint laxity for the evaluation of elbow joints with implant replacements and other surgical treatment modalities.
Positron emission tomography predicts transplantation outcome
Inwards, David J.

Mayo Clinic

Blood | June 19, 2003 | Volume: 102 | Issue: 1 | Pages: 2-2

10.1182/blood-2003-04-1333 Get It

American College of Cardiology/American Heart Association Clinical Practice Guidelines: Part I
Gibbons, Raymond J. , Smith, Sidney C. , Antman, Elliott M.

Mayo Clinic

Circulation | June 18, 2003 | Volume: 107 | Issue: 23 | Pages: 2979-2986

10.1161/01.cir.0000063682.20730.a5 | PMID 12814985 Get It

Phase III Trial of Paclitaxel at Two Dose Levels, the Higher Dose Accompanied by Filgrastim at Two Dose Levels in Platinum-Pretreated Epithelial Ovarian Cancer: An Intergroup Study
Omura, George, Brady, Mark F. , Look, Katherine Y., Averette, Hervy E., Delmore, James E., Long, Harry J., Wadler, Scott, Spiegel, Gregory, Arbuck, Susan G.

Mayo Clinic

Journal of Clinical Oncology | June 17, 2003 | Volume: 21 | Issue: 15 | Pages: 2843-2848

10.1200/jco.2003.10.082 | PMID 12807937 Get It

Purpose: To determine if increasing the dose of paclitaxel increases the probability of clinical response, progression-free survival, or overall survival in women who have persistent or recurrent ovarian cancer, and whether doubling the dose of prophylactic filgrastim accompanying the higher paclitaxel dose decreases the frequency of neutropenic fever. Patients and Methods: Consenting patients with persistent, recurrent, or progressing ovarian cancer, despite first-line platinum therapy (but no prior taxane), were randomly assigned to paclitaxel 135 mg/m2, 175 mg/m2, or 250 mg/m2 over 24 hours every 3 weeks. Patients receiving paclitaxel 250 mg/m2 were also randomly assigned to 5 or 10 μg/kg of filgrastim per day subcutaneously. Results: Accession to the paclitaxel 135-mg/m2 arm was closed early. Among the 271 patients on the other regimens with measurable disease, partial and complete response on paclitaxel 250 mg/m2 (36%) was significantly higher than on 175 mg/m2 (27%, P = .027). This difference was more evident among patients who never responded to prior platinum. However, progression-free and overall survival results were similar. The median durations of overall survival were 13.1 and 12.3 months for paclitaxel 175 mg/m2 and 250 mg/m2, respectively. Thrombocytopenia, neuropathy, and myalgia were greater with paclitaxel 250 mg/m2 (P < .05). The incidence of neutropenic fever after the first cycle of paclitaxel 250 mg/m2 was 19% and 18% on the 5-μg/kg and 10-μg/kg filgrastim dose, respectively (22% for paclitaxel 175 mg/m2 without filgrastim). Conclusion: Paclitaxel exhibits a dose effect with regard to response rate, but there is more toxicity and no survival benefit to justify paclitaxel 250 mg/m2 plus filgrastim. Doubling the filgrastim dose from 5 to 10 μg/kg did not reduce the probability of neutropenic fever after high-dose paclitaxel.
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma
Fonseca, Rafaël , Debes-Marun, Carina, Picken, Elisa B., Dewald, Gordon W., Bryant, Sandra C. , Winkler, Jerry M., Blood, Emily, Oken, Martin M., Santana-Dávila, Rafael , González-Paz, Natalia, Kyle, Robert A. , Dispenzieri, Angela , Lacy, Martha Q. , Greipp, Philip R., Gertz, Morie A. , Dispenzieri, Angela , Fonseca, Rafael

Mayo Clinic

Blood | June 17, 2003 | Volume: 102 | Issue: 7 | Pages: 2562-2567

10.1182/blood-2003-02-0493 | PMID 12805059 Get It

Abstract Aneuploid is ubiquitous in multiple myeloma (MM), and 4 cytogenetic subcategories are recognized: hypodiploid (associated with a shorter survival), pseudodiploid, hyperdiploid, and near-tetraploid MM. The hypodiploid, pseudodiploid, and near-tetraploid karyotypes can be referred to as the nonhyperdiploid MM. Immunoglobulin heavy-chain (IgH) translocations are seen in 60% of patients. We studied the relation between aneuploidy and IgH translocations in MM. Eighty patients with MM and abnormal metaphases were studied by means of interphase fluorescent in situ hybridization (FISH) to detect IgH translocations. We also studied a second cohort of 199 patients (Eastern Cooperative Oncology Group [ECOG]) for IgH translocations, chromosome 13 monosomy/deletions (Δ13), and ploidy by DNA content. Mayo Clinic patients with abnormal karyotypes and FISH-detected IgH translocation were more likely to be nonhyperdiploid (89% versus 39%, P &lt; .0001). Remarkably, 88% of tested patients with hypodiploidy (16 of 18) and 90% of tested patients with tetraploidy (9 of 10) had an IgH translocation. ECOG patients with IgH translocations were more likely to have nonhyperdiploid MM by DNA content (68% versus 21%, P &lt; .001). This association was seen predominantly in patients with recurrent chromosome partners to the IgH translocation (11q13, 4p16, and 16q23). The classification of MM into hyperdiploidy and nonhyperdiploidy is dictated largely by the recurrent (primary) IgH translocations in the latter. (Blood. 2003;102:2562-2567)
Fibrotic Idiopathic Interstitial Pneumonia
Latsi, P., Bois, Roland M. du, Colby, Thomas V. , Βisirtzoglou, Danai , Nikolakopoulou, Ageliki, Veeraraghavan, Srihari , Hansell, David M., Wells, Athol U. , Nicholson, Andrew G.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 9, 2003 | Volume: 168 | Issue: 5 | Pages: 531-537

10.1164/rccm.200210-1245oc | PMID 12791580 Get It

Abstract Survival is linked to the histopathologic distinction between usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), the most commonly encountered fibrotic idiopathic interstitial pneumonia. We retrospectively compared the prognostic significance of histopathologic diagnoses, baseline pulmonary function indices, and serial trends in pulmonary function indices (diffusing capacity, FVC, FEV1, the recently defined composite physiologic index) at 6 and 12 months in 104 patients (UIP, n = 63; fibrotic NSIP, n = 41). Survival was lower in UIP than in fibrotic NSIP (p = 0.001) but not in patients with severe functional impairment; mortality during the first 2 years was linked solely to the severity of functional impairment at presentation. The composite physiologic index was the strongest determinant of outcome (p &lt; 0.001). At 6 months, serial diffusing capacity levels (p = 0.003) and histopathologic diagnosis (p = 0.002) were prognostically equivalent. At 12 months, serial pulmonary function trends were the only major prognostic determinant (p &lt; 0.0005 for all variables), with no independent significance associated with the distinction between UIP and fibrotic NSIP. We conclude that at 12 months, serial pulmonary function trends have considerable prognostic value in UIP and NSIP. Their histologic distinction provides no additional prognostic information when pulmonary function trends are clear cut or when functional impairment is severe.
Immunophenotyping Combined with Laser Capture Microdissection (Immuno-LCM)
Jin, Long , Ruebel, Katharina H., Bayliss, Jill , Kobayashi, Ikuo , Lloyd, Ricardo V.

Mayo Clinic

ACTA HISTOCHEMICA ET CYTOCHEMICA | June 6, 2003 | Volume: 36 | Issue: 1 | Pages: 9-13

10.1267/ahc.36.9 Get It

Cardiovascular Endocrinology: Introduction
Baxter, John D. , Webb, Paul , Young, William F.

Mayo Clinic

Endocrine Reviews | June 4, 2003 | Volume: 24 | Issue: 3 | Pages: 253-260

10.1210/er.2003-0099 | PMID 12788796 Get It

Oxidized Low-Density Lipoprotein Activates Migration and Degranulation of Human Granulocytes
Sedgwick, Julie B., Hwang, Young Sil, Gerbyshak, Heather A., Kita, Hirohito , Busse, William W. , Kita, H

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | June 3, 2003 | Volume: 29 | Issue: 6 | Pages: 702-709

10.1165/rcmb.2002-0257oc | PMID 12777245 Get It

Abstract Oxidized low-density lipoprotein (oxLDL) has been reported as a major participant in the pathogenesis of atherosclerosis. We hypothesized that oxLDL can also interact with granulocytes during inflammatory airway diseases, such as asthma. To test the chemotactic effect of oxLDL, isolated human peripheral granulocytes were added to the upper chambers of Transwell filters and migration in response to oxLDL was determined. Cu+2-oxidized LDL stimulated neutrophil (23.4 ± 3.2% for 100 μg/ml oxLDL versus 2.9 ± 1.1% for buffer, P &lt; 0.05) and eosinophil (19.3 ± 3.5% versus 0.6 ± 0.02% for buffer, P &lt; 0.05) chemotaxis in a concentration-dependent manner. The magnitude of chemotaxis was dependent on the degree of LDL oxidation. Granulocyte transmigration across IL-1β–activated human pulmonary microvascular endothelial cell monolayers was similarly stimulated by oxLDL. OxLDL activated significant degranulation of both neutrophils (100.9 ± 9.8 versus 49.6 ± 8.4 ng lactoferrin released/5 × 105 neutrophils for buffer, P &lt; 0.05) and eosinophils (342 ± 115.4 versus 85.8 ± 30.4 ng eosinophil-derived neurotoxin/1 × 106 eosinophils for buffer, P &lt; 0.05). Therefore, in vivo influx and oxidation of LDL may be an important mediator for the initiation of bronchial inflammation where granulocytes are recruited to the lung.
Prognostic Implications of Physiologic and Radiographic Changes in Idiopathic Interstitial Pneumonia
Flaherty, Kevin R. , Mumford, Jeanette A. , Murray, Susan , Kazerooni, Ella A. , Gross, Barry H., Colby, Thomas V. , Flint, Andrew , Toews, Galen B., Lynch, Joseph P., Travis, William D. , Martínez, Fernando J.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 3, 2003 | Volume: 168 | Issue: 5 | Pages: 543-548

10.1164/rccm.200209-1112oc | PMID 12773329 Get It

Abstract Idiopathic interstitial pneumonias are a diverse group of lung diseases with varied prognoses. We hypothesized that changes in physiologic and radiographic parameters would predict survival. We retrospectively examined 80 patients with usual interstitial pneumonia and 29 patients with nonspecific interstitial pneumonia. Baseline characteristics were examined together with 6-month change in forced vital capacity, diffusing capacity for carbon monoxide, and ground glass infiltrate and fibrosis on high resolution computed tomography. Patients with usual interstitial pneumonia were more likely to have a statistically significant or marginally significant decline in lung volume, diffusing capacity for carbon monoxide, and an increase in ground glass infiltrates (p ⩽ 0.08) compared with patients with nonspecific interstitial pneumonia. For patients with usual interstitial pneumonia, change in forced vital capacity was the best physiologic predictor of mortality (p = 0.05). In a multivariate Cox proportional hazards model controlling for histopathologic diagnosis, gender, smoking history, baseline forced vital capacity, and 6-month change in forced vital capacity, a decrease in forced vital capacity remained an independent risk factor for mortality (decrease &gt; 10%; hazard ratio 2.47; 95% confidence interval 1.29, 4.73; p = 0.006). We conclude that a 6-month change in forced vital capacity gives additional prognostic information to baseline features for patients with idiopathic interstitial pneumonia.